DC Mental Health Access in Pediatrics: Evaluating a Child Psychiatry Access Program in Washington, DC.

Introduction: Child psychiatry access programs (CPAPs) provide primary care providers (PCPs) with assistance in mental health diagnosis, management, and resource navigation.

Method: Data collected from DC Mental Health Access in Pediatrics (MAP) included PCPs and patient demographics, clinical encounter information, and provider satisfaction.

Results: DC MAP consult volume increased 349.

Promoting glycemic control in young children with type I diabetes: Results from a pilot intervention for parents.

Objective: Nutrition and physical activity are key components of daily diabetes care in young children with type I diabetes (T1D). Normative developmental behavioral challenges related to nutrition and physical activity complicate management of T1D. The current pilot study evaluated the feasibility, acceptability, and indications of behavior change of an intervention aimed at improving nutrition and physical activity in young children with T1D.

The current state of parent feeding behavior, child eating behavior, and nutrition intake in young children with type 1 diabetes.

Background: One integral component of type 1 diabetes (T1D) management is attention to nutrition, which can be particularly challenging in young children.

Objective: The current study reports on parent and child eating/feeding behavior and nutrition intake as compared with current recommendations for pediatric T1D.

Subjects: Participants were 46 children ages 2 to 5 diagnosed with T1D and one parent.

Young Children with Type 1 Diabetes: Sleep, Health-Related Quality of Life, and Continuous Glucose Monitor Use.

While children with type 1 diabetes (T1D) and their parents report significant sleep problems, few studies have focused on young children and included health-related quality of life (HRQOL) as an outcome of sleep disturbance. In addition, relatively little is known about the use of diabetes devices, such as continuous glucose monitors (CGMs), in young children and their link with sleep disturbances. This brief report examines the relationship between sleep quality and HRQOL and explores sleep disturbances related to CGM use in a sample of young children with T1D.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Purpose: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated this ADC as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers.

Experimental Design: Sacituzumab govitecan was administered on days 1 and 8 of 21-day cycles, with cycles repeated until dose-limiting toxicity or progression.